Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study – The Lancet

Oct 10, 2022 by The Beat Maker - 0 Comments

If you don’t remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Please enter a term before submitting your search.
Access provided by
Usmani S, Berdeja J, Madduri D, et al. EP964: Updated CARTITUDE-1 results of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy. Replased/refractory multiple myeloma. European Hematology Association; June 4–17, 2021 (abstr EP964).
DOI: https://doi.org/10.1016/S2352-3026(22)00284-8
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.
Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

Privacy Policy   Terms and Conditions   Accessibility

RELX

source

Leave a Comment